TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01421927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Start between Day+100 and Day+120 post-transplant~- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~- Duration~* until persistent stringent complete response for 3 months~* or progression defined by IMWG criteria12~* or unacceptable toxicity~* or one year after transplant
Study: NCT03945591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV over 2 hours on Day +3 and +4
Study: NCT02982590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG Oral Tablet [ELIQUIS]
Description: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin Sodium
Description: as controlled arm since warfarin is the standard therapy for LV thrombus
Study: NCT00785044

Intervention type: DRUG
Intervention: I-123 mIBG
Description: This was an observational study. Participants were previously dosed in separate study.
Study: NCT01628107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Intravenous (IV) injection
Study: NCT02047682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biopsychosocial

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Study: NCT01976520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncoquest-CLL vaccine
Description: Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
Study: NCT02278562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anakinra
Description: 100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
Study: NCT04330404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive strategy training
Description: The Cognitive strategy training, including awareness enhancement, cognitive-related education, discussion of everyday cognitive difficulties, generation of cognitive strategies, cognitive strategy practice, and homework assignments
Study: NCT02278562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: actos
Description: 30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules and injection
Study: NCT01830855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months (lot 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months (lot 2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: 0.5 mL dose, given at 0, 2 and 6 months (lot 3)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix (HAV)
Description: 0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 0.5 mL dose of sterile normal saline for injection.
Study: NCT03832803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empty bladder
Description: No drinking protocol.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Full bladder
Description: Followed drinking protocol
Study: NCT02107495

Intervention type: DEVICE
Intervention: Samsung LABGEO IVD-A20 CHF Test

Intervention type: DEVICE
Intervention: Samsung LABGEO IVD-A20 CHF Test

Intervention type: DEVICE
Intervention: Samsung LABGEO IVD-A20 CHF Test
Study: NCT05500820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A repeat oral dose of CIN-107 once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A repeat oral dose of CIN-107 once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A repeat oral dose of CIN-107 once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A repeat oral dose of CIN-107 once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: A repeat oral dose of CIN-107 once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A repeat oral dose of matching placebo once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A repeat oral dose of matching placebo once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A repeat oral dose of matching placebo once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A repeat oral dose of matching placebo once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A repeat oral dose of matching placebo once daily for 10 days.
Study: NCT00382239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide (LY2148568)
Description: subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide (LY2148568)
Description: subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide (LY2148568)
Description: subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection twice daily, 0.02 mL to 0.04 mL
Study: NCT02895620

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Xpert bladder Test
Description: Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
Study: NCT04330404

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group interactive game
Description: The active control group will receive group interactive game, including table games and games using songs, balloons, newspapers and so on.
Study: NCT03585764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv19-BBz CAR T cells
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv19-BBz CAR T cells
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv19-BBz CAR T cells
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOv19-BBz CAR T cells
Description: intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Folate Receptor expression test
Description: Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Folate Receptor expression test
Description: Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Folate Receptor expression test
Description: Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Folate Receptor expression test
Description: Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
Study: NCT04659876

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical features and laboratory values
Description: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical features and laboratory values
Description: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
Study: NCT00967070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
Study: NCT04257448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Powder and solvent for solution for infusion; Intravenous use
Study: NCT00621751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 800 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01937936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
Study: NCT03805997

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dietary advice
Description: participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of Bleu-Blanc-Coeur products
Description: consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No consumption of Bleu-Blanc-Coeur products
Description: no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact
Description: Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: food questionnaire
Description: Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food questionnaire
Description: Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: newborn faeces sample
Description: Newborn faeces sample will be collected at 21 Days post partum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: newborn faeces sample
Description: Newborn faeces sample will be collected at 21 Days post partum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: breast milk sample
Description: Breast milk sample will be collected at 21 days and 45 days post partum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk sample
Description: Breast milk sample will be collected at 21 days and 45 days post partum
Study: NCT01048749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aquatic vertical suspension.
Description: Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: land-based supine flexion
Description: The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
Study: NCT00739011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 254/244 CPAP series CPAP humidifier
Description: Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
Study: NCT02163187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the InterStimTM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the InterStimTM

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSK BFI questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSK BFI questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Low Anterior Resection Score (LARS) questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Low Anterior Resection Score (LARS) questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EuroQOL5D questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EuroQOL5D questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires
Study: NCT02571127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hidra1
Description: Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.
Study: NCT04533555

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Broad gene panel for young adult cancers
Description: Genetic testing will occur using a broad gene panel for young adult cancers

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Those in the standard group who are considered high risk will have genetic testing done using the standard of care panel as selected by their care provider.
Study: NCT02774512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
Study: NCT04195048

Intervention type: OTHER
Intervention: Risk factors
Description: Risk factors: modifiable and unmodifiable risk factors

Intervention type: OTHER
Intervention: Risk factors
Description: Risk factors: modifiable and unmodifiable risk factors
Study: NCT01101438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT04625842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group interview
Description: Group interview with patients who received radiation treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group interview
Description: Group interview with patients who received radiation treatment
Study: NCT01444742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)
Study: NCT01163812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Description: Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved.
Study: NCT03138187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Description: The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
Study: NCT01715753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: \> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling and group education lessons
Description: Individual and group diet counseling to achieve a \>10% weight loss
Study: NCT04603885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: stretching exercise
Study: NCT04457180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib will be administered daily from on D5 through D16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide will be administered daily on D1 and D12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be administered daily on D2 and D13